Citigroup Inc Metacrine, Inc. Transaction History

Citigroup Inc

  • $169 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022
SELL
$0.36 - $0.63 $1,073 - $1,878
-2,982 Closed
0 $0
Q1 2022

May 12, 2022
BUY
$0.43 - $0.7 $1,282 - $2,087
2,982 New
2,982 $2,000

Others Institutions Holding MTCR

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Metacrine, Inc.

MTCR Quotes by TradingView
  • Ticker MTCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,569,500
  • Description
  • Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
More about MTCR
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email